HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era

被引:25
作者
Gountas, Ilias [1 ,2 ]
Sypsa, Vana [1 ]
Blach, Sarah [2 ]
Razavi, Homie [2 ]
Hatzakis, Angelos [1 ]
机构
[1] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece
[2] Ctr Dis Anal, Lafayette, CO USA
关键词
HEPATITIS-C VIRUS; ANTIVIRAL TREATMENT; PREVENTION; INFECTION; REINFECTION; IMPACT; INTERVENTIONS; EPIDEMIOLOGY; TRANSMISSION; PROJECTIONS;
D O I
10.1371/journal.pone.0202109
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Elimination of hepatitis C virus (HCV) among people who inject drugs (PWID) is a costly investment, so strategies should not only focus on eliminating the disease, but also on preventing disease resurgence. The aims of this study are to compute the minimum necessary antiviral therapies to achieve elimination with and without the additional expansion of harm reduction (HR) programs and to examine the sustainability of HCV elimination after 2030 if treatment is discontinued. Method We considered two types of epidemic (with low (30%) and high (50%) proportion of PWID who engage in sharing equipment (sharers)) within three baseline chronic HCV (CHC) prevalence settings (30%, 45% and 60%), assuming a baseline HR coverage of 40%. We define sustainable elimination strategies, those that could maintain eliminations results for a decade (2031-2040), in the absence of additional treatment. Results The model shows that the optimum elimination strategy is dependent on risk sharing behavior of the examined population. The necessary annual treatment coverage to achieve HCV elimination under 45% baseline CHC prevalence, without the simultaneous expansion of HR programs, ranges between 4.7-5.1%. Similarly, under 60% baseline CHC prevalence the needed treatment coverage varies from 9.0-10.5%. Increasing HR coverage from 40% to 75%, reduces the required treatment coverage by 6.5-9.8% and 11.0-15.0% under 45% or 60% CHC prevalence, respectively. In settings with <= 45% baseline CHC prevalence, expanding HR to 75% could prevent the disease from rebounding after elimination, irrespective of the type of the epidemic. In high chronic HCV prevalence, counseling interventions to reduce sharing are also needed to maintain the HCV incident cases in low levels. Conclusions Harm reduction strategies have a vital role in HCV elimination strategy, as they reduce the required number of treatments to eliminate HCV and they provide sustainability after the elimination. The above underlines that HCV elimination strategies should be built upon the existing HR services, and argue for HR expansion in countries without services.
引用
收藏
页数:15
相关论文
共 42 条
[1]   Elimination on the agenda for hepatitis C [J].
Burki, Talha .
LANCET INFECTIOUS DISEASES, 2014, 14 (06) :452-453
[2]  
Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P603
[3]   A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel [J].
Cornberg, Markus ;
Razavi, Homie A. ;
Alberti, Alfredo ;
Bernasconi, Enos ;
Buti, Maria ;
Cooper, Curtis ;
Dalgard, Olav ;
Dillion, John F. ;
Flisiak, Robert ;
Forns, Xavier ;
Frankova, Sona ;
Goldis, Adrian ;
Goulis, Ioannis ;
Halota, Waldemar ;
Hunyady, Bela ;
Lagging, Martin ;
Largen, Angela ;
Makara, Michael ;
Manolakopoulos, Spilios ;
Marcellin, Patrick ;
Marinho, Rui T. ;
Pol, Stanislas ;
Poynard, Thierry ;
Puoti, Massimo ;
Sagalova, Olga ;
Sibbel, Scott ;
Simon, Krzysztof ;
Wallace, Carolyn ;
Young, Kendra ;
Yurdaydin, Cihan ;
Zuckerman, Eli ;
Negro, Francesco ;
Zeuzem, Stefan .
LIVER INTERNATIONAL, 2011, 31 :30-60
[4]   Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database [J].
Cornish, Rosie ;
Macleod, John ;
Strang, John ;
Vickerman, Peter ;
Hickman, Matt .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 :928
[5]  
Cousien A, 2016, HEPATOLOGY, V63, P1090, DOI 10.1002/hep.28227
[6]  
EMCDDA, 2017, STAT B 2017 HLTH SOC
[7]   Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin [J].
Feld, Jordan J. ;
Kowdley, Kris V. ;
Coakley, Eoin ;
Sigal, Samuel ;
Nelson, David R. ;
Crawford, Darrell ;
Weiland, Ola ;
Aguilar, Humberto ;
Xiong, Junyuan ;
Pilot-Matias, Tami ;
DaSilva-Tillmann, Barbara ;
Larsen, Lois ;
Podsadecki, Thomas ;
Bernstein, Barry .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (17) :1594-1603
[8]   Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe [J].
Fraser, Hannah ;
Martin, Natasha K. ;
Brummer-Korvenkontio, Henrikki ;
Carrieri, Patrizia ;
Dalgard, Olav ;
Dillon, John ;
Goldberg, David ;
Hutchinson, Sharon ;
Jauffret-Roustide, Marie ;
Kaberg, Martin ;
Matser, Amy A. ;
Maticic, Mojca ;
Midgard, Havard ;
Mravcik, Viktor ;
Ovrehus, Anne ;
Prins, Maria ;
Reimer, Jens ;
Robaeys, Geert ;
Schulte, Bernd ;
van Santen, Daniela K. ;
Zimmermann, Ruth ;
Vickerman, Peter ;
Hickman, Matthew .
JOURNAL OF HEPATOLOGY, 2018, 68 (03) :402-411
[9]   Scaling-up HCV prevention and treatment interventions in rural United Statesmodel projections for tackling an increasing epidemic [J].
Fraser, Hannah ;
Zibbell, Jon ;
Hoerger, Thomas ;
Hariri, Susan ;
Vellozzi, Claudia ;
Martin, Natasha K. ;
Kral, Alex H. ;
Hickman, Matthew ;
Ward, John W. ;
Vickerman, Peter .
ADDICTION, 2018, 113 (01) :173-182
[10]   Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C [J].
Gane, Edward J. ;
Stedman, Catherine A. ;
Hyland, Robert H. ;
Ding, Xiao ;
Svarovskaia, Evguenia ;
Symonds, William T. ;
Hindes, Robert G. ;
Berrey, M. Michelle .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (01) :34-44